stacks_image_6471AA0C-1B9A-4C43-83ED-DF607809DABB
Vaccines

The most successful experimental vaccine to date is made with live attenuated infective larvae [1,2,3]. However, these vaccines are not suitable for widespread use in humans, and therefore other types of vaccines are being studied.

Staff at the Allen Parasite Immunology Lab are developing a DNA vaccine against filariasis.

stacks_image_D9DBEFBF-9286-4583-B50E-5B99C79EB5B8
Reference List

[1] Martin, C., Saeftel, M., Vuong, P. N., Babayan, S., Fischer, K., Bain, O., & Hoerauf, A. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun, (2001), 69(11), 7067-7073.

[2] Le Goff L, Martin C, Oswald IP, Vuong PN, Petit G, Ungeheuer MN, Bain O. Parasitology and immunology of mice vaccinated with irradiated Litomosoides sigmodontis larvae. Parasitology. 2000 Mar;120 ( Pt 3):271-80.

[3] Babayan, S. A., Attout, T., Harris, A., Taylor, M. D., Le Goff, L., Vuong, P. N., Renia, L., Allen, J. E., & Bain, O. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol, (2006), 36(8), 903-914.